Arvinas Stock Price, News & Analysis

Arvinas (ARVN) announced key updates and milestones for 2025, focusing on its protein degradation drug pipeline. The company plans to initiate two Phase 3 combination trials for vepdegestrant in breast cancer treatment: a first-line trial combining with Pfizer's atirmociclib and a second-line trial with a CDK4/6 inhibitor, both starting in 2025.

Key upcoming milestones include: topline data from VERITAC-2 Phase 3 monotherapy trial in Q1 2025, initial data presentation from ARV-102 for Parkinson's disease, and preliminary results from ARV-393 Phase 1 trial in B-cell lymphomas. The company also plans to submit an IND for a PROTAC KRAS G12D degrader.

In corporate news, Alex Santini has been appointed interim Chief Commercial Officer, effective January 17, 2025, replacing John Northcott.

Arvinas (ARVN) and Pfizer (PFE) announced preliminary Phase 1b data from the TACTIVE-U sub-study evaluating vepdegestrant in combination with abemaciclib for breast cancer treatment. The study showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% in patients previously treated with CDK4/6 inhibitors.

The trial demonstrated a tolerable safety profile using abemaciclib 150mg twice daily with vepdegestrant 200mg once daily. No significant drug-drug interactions were observed. The most common side effects included diarrhea, nausea, and fatigue, with no grade 4 or 5 adverse events reported.

As of August 30, 2024, five patients remained on study treatment. The results support the ongoing Phase 2 portion of the study.

Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focused on targeted protein degradation, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Chief Medical Officer Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer Andrew Saik will engage in a fireside chat on Tuesday, December 3 at 2:30 p.m. ET in New York. The presentation will be accessible via live audio webcast on the company's website under the Events and Presentations section.

Arvinas announced three poster presentations for vepdegestrant at the 2024 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant, a PROTAC estrogen receptor degrader, is being jointly developed with Pfizer for treating ER+/HER2- breast cancer. The presentations will cover: combination therapy with palbociclib in CDK4/6 inhibitor-resistant models, preliminary Phase 1b results of vepdegestrant plus abemaciclib in advanced breast cancer, and CYP3A4-mediated drug interaction risks when combined with CDK4/6 inhibitors and everolimus. The posters will be presented on December 12, 2024.

Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two major investor conferences. The company will be present at the Guggenheim Securities Healthcare Innovation Conference on November 13, where Chief Medical Officer Noah Berkowitz and Chief Business Officer Randy Teel will join a fireside chat. Additionally, on November 19, Berkowitz and Chief Financial Officer Andrew Saik will participate in a fireside chat at the Jefferies London Healthcare Conference. Live audio webcasts of both presentations will be accessible through the company's website and dedicated links.

Arvinas (ARVN) reported Q3 2024 financial results with revenue of $102.4 million, up from $34.6 million in Q3 2023. The company maintains $1.1 billion in cash and equivalents, expected to fund operations into 2027. Key developments include ongoing enrollment in multiple clinical studies for vepdegestrant in breast cancer, with topline data from VERITAC-2 Phase 3 trial expected in Q4 2024 or Q1 2025. Research and development expenses were $86.9 million, while general and administrative expenses increased to $75.8 million, including a $43.4 million lease termination loss.

Arvinas, a clinical-stage biotechnology company, held its third annual Arvinas Impact Day, a company-wide day of service. Employees from 16 states participated in various volunteer activities across the Greater New Haven area and beyond. The event aligns with Arvinas' core values and aims to make a positive impact in local communities.

Highlights from the day include:

• Save the Sound: Collected over 287 pounds of trash to protect local wildlife and environments
• Boys and Girls Club of Greater New Haven: Beautified indoor and outdoor spaces at two locations
• Friends of East Rock Park: Maintained walking paths by laying crushed stone and cutting back brush
• Employee-Selected Activities: Ranged from food bank support to animal shelters and neighborhood clean-ups

John Houston, Ph.D., Chairperson, CEO, and President at Arvinas, expressed pride in the employees' dedication and enthusiasm in supporting vital community organizations.

Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has announced its upcoming third quarter 2024 financial results and corporate update webcast. The event is scheduled for Wednesday, October 30, 2024, at 8:00 a.m. ET.

Investors and interested parties can access the live webcast through the 'Events and Presentations' section on the company's investor page. For those unable to attend the live event, a replay will be made available on the Arvinas website following the presentation.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two upcoming investor conferences:

• The Wells Fargo Healthcare Conference on September 5, 2024, featuring a fireside chat with Ian Taylor, Ph.D., President of R&D, and Randy Teel, Ph.D., Chief Business Officer.
• The Cantor Global Healthcare Conference on September 19, 2024, with Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, participating in a fireside chat.

Both presentations will be available via live audio webcast on the company's website and through provided links. This engagement with investors highlights Arvinas' commitment to transparency and shareholder communication.